Epistem Holdings Plc
("Epistem" or the "Company")
18 December 2013
Results of AGM
Epistem Holdings plc (LSE: EHP), the biotechnology and personalised medicine company, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.
For further details please contact:
Epistem Holdings PLC |
|
Matthew Walls, Chief Executive Officer |
Tel: 0161 606 7258 |
John Rylands, Finance Director |
Tel: 0161 606 7244 |
|
|
Walbrook PR |
Tel: 0207 933 8780 |
Mike Wort/Anna Dunphy |
|
|
|
Peel Hunt LLP |
Tel: 020 7418 8900 |
James Steel |
|
Notes to Editors:
About Epistem
Epistem is a biotechnology and personalised medicine company commercialising its expertise in epithelial stem cells and pharmacogenomics in the areas of oncology, gastrointestinal, dermatological and infectious disease.
Epistem develops innovative therapeutics, biomarkers and diagnostics alongside providing preclinical services to drug development companies. Epistem's core expertise is focused on the regulation of adult stem cells located in epithelial tissue which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem also has a range of proprietary amplification (RNA and DNA) technologies for use in drug discovery, development and diagnostics.